Redeye comments on W5’s Q1-results which were softer than expected while the order intake remained s...
Investors House reported Q1 revenues of EUR 2.7m, 4% below our estimate.
Redeye returns with a more in-depth take on OssDsign’s Q1 report.
Redeye comments on G5’s Q1-results which saw a weaker topline than expected and while reported EBIT ...
Redeye updates its estimates following Freemelt’s Q1 report, which came in lower than expected in te...
Redeye provides an update following Optomed’s Q1 2025 report.
Acconeer's first quarter 2025 net sales growth of 20% y/y (or -12% adjusted for the postponed order)...
Redeye comments on the outcome of AcouSort’s rights issue.
NoHo Partners' Q1 2025 results missed Vara Research expectations on several items, but we argue that...
Redeye retains its positive view of Teneo AI despite a Q1 report on the soft side.
Soft Q1 sales of SEK 2.9m on no machine deliveries, but 6 orders Share issue readies balance sheet f...
Delivery on both sales and gross margin above expectations EBIT revised up by 11-22% for '25e-'27e F...
Sales -13% vs cons, EBIT -60%, post a strong Q4 and tough comps Guides for higher military budgets p...
EBITA SEK 271m (+3% vs. ABG, +6% vs. IR cons) We expect cons EBITA upgrades of 3-4% for '25e 15-13x ...
Redeye is revising near-term forecasts and valuation, following a weak Q1 and current market headwin...
